TY - JOUR
T1 - High nuclear poly-(ADP-ribose)-polymerase expression is prognostic of improved survival in pancreatic cancer
AU - Klauschen, Frederick
AU - von Winterfeld, Moritz
AU - Stenzinger, Albrecht
AU - Sinn, Bruno V.
AU - Budczies, Jan
AU - Kamphues, Carsten
AU - Bahra, Marcus
AU - Wittschieber, Daniel
AU - Weichert, Wilco
AU - Striefler, Jana
AU - Riess, Hanno
AU - Dietel, Manfred
AU - Denkert, Carsten
PY - 2012/9
Y1 - 2012/9
N2 - Aims: Poly-(ADP-ribose)-polymerases (PARPs) act as post-translational modifiers of proteins that are mainly involved in the DNA repair machinery, and have recently been shown to be predictive of pathologically complete remission after chemotherapy in breast cancer. In the pancreas, PARP expression has so far only been studied in inflammatory conditions. Therefore, in this study, we investigated the relevance of PARP in pancreatic cancer. Methods and results: Cytoplasmic and nuclear PARP expression was assessed by immunohistochemistry in a population-based cohort of 178 adenocarcinomas of the pancreas and correlated with clinicopathological parameters. We found that low-level nuclear expression of PARP is associated with a poor prognosis (median survival 9.6 versus 14.5months, P=0.004). Conclusions: Our analysis shows that nuclear PARP is an independent prognostic marker with respect to standard clinicopathological parameters. These results suggest that PARP should be further explored as a predictive factor with respect to conventional chemotherapy and concepts of PARP inhibitor therapy in pancreatic cancer.
AB - Aims: Poly-(ADP-ribose)-polymerases (PARPs) act as post-translational modifiers of proteins that are mainly involved in the DNA repair machinery, and have recently been shown to be predictive of pathologically complete remission after chemotherapy in breast cancer. In the pancreas, PARP expression has so far only been studied in inflammatory conditions. Therefore, in this study, we investigated the relevance of PARP in pancreatic cancer. Methods and results: Cytoplasmic and nuclear PARP expression was assessed by immunohistochemistry in a population-based cohort of 178 adenocarcinomas of the pancreas and correlated with clinicopathological parameters. We found that low-level nuclear expression of PARP is associated with a poor prognosis (median survival 9.6 versus 14.5months, P=0.004). Conclusions: Our analysis shows that nuclear PARP is an independent prognostic marker with respect to standard clinicopathological parameters. These results suggest that PARP should be further explored as a predictive factor with respect to conventional chemotherapy and concepts of PARP inhibitor therapy in pancreatic cancer.
KW - Immunohistochemistry
KW - Pancreatic cancer
KW - Poly-(ADP-ribose)-polymerase
KW - Prognostic biomarker
UR - http://www.scopus.com/inward/record.url?scp=84865393927&partnerID=8YFLogxK
U2 - 10.1111/j.1365-2559.2012.04225.x
DO - 10.1111/j.1365-2559.2012.04225.x
M3 - Article
C2 - 22384823
AN - SCOPUS:84865393927
SN - 0309-0167
VL - 61
SP - 409
EP - 416
JO - Histopathology
JF - Histopathology
IS - 3
ER -
